Inclusion Criteria:

1. Prior allogeneic hematopoietic stem cell transplant using either bone marrow, peripheral blood stem cells or cord blood. Recipients of non-myeloablative transplants are also eligible.

2. CMV, adenovirus or EBV infection persistent despite standard therapy

   1. CMV infection defined as: i.Patients with CMV disease: defined as the demonstration of CMV by biopsy specimen from visceral sites (by culture or histology) or the detection of CMV by culture or direct fluorescent antibody stain in bronchoalveolar lavage fluid in the presence of new or changing pulmonary infiltrates OR ii. Failure of antiviral therapy: defined as the continued presence of pp65 antigenemia (>1+ cell/100,000 cells) or DNAemia (as defined by reference lab performing PCR assay but usually >400 copies/ml) after at least 7 days of antiviral therapy OR iii. Relapse after antiviral therapy defined as recurrence of either pp65 antigenemia or DNAemia after at least 2 weeks of antiviral therapy
   2. EBV infection is defined as: i. Biopsy proven lymphoma with EBV genomes detected in tumor cells by immunocytochemistry or in situ PCR ii. Or clinical or imaging findings consistent with EBV lymphoma and elevated EBV viral load in peripheral blood.
   3. Adenovirus infection is defined as the presence of adenoviral positivity as detected by PCR, DAA or culture from ONE site such as stool or blood or urine or nasopharynx. Adenovirus disease will be defined as the presence of adenoviral positivity as detected by culture from more than two sites such as stool or blood or urine or nasopharynx
   4. Standard therapy is defined as: i.For CMV infection, 7 days therapy with Ganciclovir, Foscarnet or Cidofovir for patients with disease (see 2.a.i) or recurrence after 14 days therapy (see 2.a.iii) ii. For EBV infection, rituximab given at 375mg/m2 in patients with a CD20+ve tumor iii. For adenovirus infection, 7 days therapy with Cidofovir (if renal function permits this agent to be given)
   5. The virus infection would be defined as progressive if: i. There was a rise or a fall of less than 50% in viral load in peripheral blood or any site of disease as measured by PCR for adenovirus, CMV or EBV (or in antigenemia levels for CMV or any other quantitative assay) ii. There was an increase or less than 50% response at sites of disease for EBV lymphoma
3. Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day prednisone.
4. Absolute neutrophil count (ANC) greater than 500/µL.
5. Written informed consent from patient, parent or guardian.
6. Education materials have been provided to, and reviewed with, patients under the age of 18.

Donors will be eligible if they meet eligibility criteria for blood donors on history and exam by a transplant donor physician and have negative infectious diseases testing for HIV-1 antibody, HIV-2 antibody, HIV NAT, HTLV-1/2 antibodies, HBs antigen, HBc antibody, HCV NAT, RPR, West Nile virus NAT, and Chagas testing

Exclusion Criteria:

1. Patients receiving ATG, or Campath or other immunosuppressive monoclonal antibodies within 28 days of screening for enrollment.

2. Patients with other uncontrolled infections. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.

   Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.

3. Patients who have received DLI within 28 days.
4. Patients with active acute GVHD grades II-IV.

Donors will be ineligible if they do not meet eligibility criteria for blood donors on the donor questionaire or have positive infectious diseases testing on any of the tests outlined in the inclusion criteria